Schonfeld Strategic Advisors LLC Sells 65,533 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Schonfeld Strategic Advisors LLC lowered its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 69.1% during the 4th quarter, Holdings Channel.com reports. The fund owned 29,317 shares of the specialty pharmaceutical company’s stock after selling 65,533 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $3,610,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in JAZZ. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at $25,000. Quadrant Capital Group LLC increased its position in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. CoreFirst Bank & Trust bought a new position in shares of Jazz Pharmaceuticals in the 4th quarter worth approximately $28,000. Allianz SE purchased a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth approximately $29,000. Finally, Jones Financial Companies Lllp grew its position in Jazz Pharmaceuticals by 75.1% during the fourth quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock valued at $37,000 after buying an additional 130 shares during the period. Hedge funds and other institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Up 2.4 %

Shares of JAZZ stock opened at $120.05 on Friday. The company’s fifty day simple moving average is $122.63 and its two-hundred day simple moving average is $122.47. Jazz Pharmaceuticals plc has a 52 week low of $95.49 and a 52 week high of $148.06. The stock has a market cap of $7.40 billion, a P/E ratio of 16.91, a PEG ratio of 1.04 and a beta of 0.42. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling

In other news, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction that occurred on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total transaction of $185,625.00. Following the sale, the chief executive officer now directly owns 440,307 shares of the company’s stock, valued at $54,487,991.25. This represents a 0.34 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CMO Robert Iannone sold 2,403 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $138.41, for a total transaction of $332,599.23. Following the completion of the transaction, the chief marketing officer now directly owns 79,621 shares of the company’s stock, valued at approximately $11,020,342.61. This trade represents a 2.93 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 28,736 shares of company stock worth $4,023,305. Corporate insiders own 4.20% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on JAZZ shares. JPMorgan Chase & Co. lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and boosted their price target for the company from $145.00 to $179.00 in a report on Friday, March 7th. Truist Financial raised their price objective on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a research note on Thursday, March 6th. Royal Bank of Canada cut their price objective on Jazz Pharmaceuticals from $179.00 to $178.00 and set an “outperform” rating for the company in a research note on Wednesday, February 26th. Finally, HC Wainwright lifted their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the company a “buy” rating in a report on Monday, March 10th. One analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.